Archives: Speakers

Nina Levin is a senior communications professional with extensive client-facing experience and a thorough understanding of corporate communications and internal and compliance processes. In her role as vice president of client success at Within3, she directs and identifies activities to meet KPIs by developing tailored strategic plans and drawing on experience across medical communications, advertising, and PR to set clients up for success. Nina’s proven track record and industry expertise allows her to deliver and oversee client support activities and apply her experience in process development, improvement, and implementation to ensure optimal results while meeting timelines and providing cost-effective deliverables.

Guillem is the Founder and CEO of MediQuo as well as the Founder of MeetingDoctors. Investor and board member of more than 30 startups including: Singularu, Cuidum, Landbot, Demium, Homyspace, Hannun, Taiga Agile, Swipcar, Catevering, Dental Residency, Brickbro, Twenix, The Wild Curl, Shimoku, Spathios, Trialing, Pulpo, Rebag, Impossible Bakers, Incapto and Buscoresi among others. He is a physician and mathematician with an MBA from IESE Business School and has deep knowledge in the eHealth market, MedTech and early seed startups. Guillem’s technical knowledge includes the areas of data-mining, signal processing, artificial intelligence and product development.

Alastair has 30+ years of experience in the biopharmaceutical development of pre- and post-approval drugs, joining Syneos Health on 2017. Prior to joining Syneos Health, Alastair had a Global Delivery Head role at AstraZeneca with responsibility for the delivery of both pre and post approval programmes supporting key brands

As a Director, Operational Strategy with over 17 years’ experience from the Pharma, Biotech and CRO side of clinical trial planning, execution and leadership, Alexis uses her expertise to support Precision for Medicine (PFM) clients. This includes the development of study and portfolio level strategies. Alexis has managed global studies from Phase I FIH to logistically complex Phase III studies and has a passion for operational excellence, process management and study finance. Alexis holds a degree in Neuroscience and a Masters in Biotechnology Law and Ethics. With a focus in Oncology and Rare Disease, PFM is now also supporting clients within Neurology, CVS and Pediatric indications.

Owen Corbin is an attorney admitted to the NC Bar (1996), CIPM, with more than 15 years of industry experience helping customers navigate a complex global regulatory landscape. He joined IQVIA in 2012 and is currently Sr. Director, DCT Regulatory and Privacy for IQVIA Decentralized Clinical Trials.

Ben Schlatka joined Medidata in 2020 through Medidata’s acquisition of MC10’s Digital Biomarker Business. After beginning his career as a corporate “intraprenuer” at IBM, Ben grew a series of successful startups including including Volunteer Solutions.org (Sold to the United Way) and Nantero (Sold to Lockheed Martin). Most recently, Ben Schlatka was co-founder & CEO of MC10, a pioneer in sensors and new end point development in clinical research. Ben is passionate about using digital technologies to transform the lives of patients, in both clinical research and clinical practice. He holds an MBA from the Harvard Business School and frequently lectures on the formation of disruptive science based businesses.

Ellen Van Strijdonck is the Operational Manager Clinical Operations at SGS Belgium Health & Nutrition, with extensive experience in the field and project management skills. Quickly after her start as Clinical Research Coordinator at the SGS CPU, she continued her career as a Project Manager in Early Phase trials and Human Challenge trials. Ellen successfully implemented eSource at SGS CPU and grew further as Head of the Clinical Project Managers. Ellen has M.Sc. BioMedical Sciences from the University of Antwerp.

More than 25 years of successful early phase drug development experience delivering pivotal registration studies​ Holds a Neuro & Molecular Pharmacology Master’s degree​ Scientific expertise includes design and delivery of cell therapies, targeted small molecules, immune-oncology clinical development plans across rare indications, solid tumor, and hematological malignancies​ Experience leading global teams and all phases of oncology clinical development programs for both large and mid-size pharmaceutical and biotechnology clients​

Anastassia is holding master’s degree in Biology and spent 5 years in cancer research laboratory to specialize thereafter in regulatory affairs, policy and patient engagement in the scope of clinical research. She was part of several IMI and EU funded projects, has been closely following the development and implementation of EU directives and regulations relevant to clinical research, including GDPR, but also others such as clinical trials regulation, in vitro medical device regulation, etc. After almost 20 years of work at headquarters of one of the largest European non-for-profit clinical research sponsor (EORTC), Anastassia joined MyData-Trust to bring her expertise at the service of a large circle of organizations active in life science.

Alina Pszczółkowska is holding a position of the Head of Study Management Late-Phase Development in Respiratory&Infection and CVRM (Cardivascular Renal Metabolic) areas, supporting AstraZeneca clinical operations worldwide. Being a physician, she has been involved in managing and leading clinical research projects for more than 20 years. Her international experience includes the leadership of AstraZeneca Site Management and Monitoring organization in 40 countries across the globe as well as 2 years spent in AZ core science site in Gothenburg, where she led program level operational management of cardiovascular portfolio. She has also had a pleasure to play one of key roles in shaping and transforming AstraZeneca’s global Clinical Trials Centre in Warsaw to become the largest and truly unique centre of this kind among all innovative pharmaceutical companies in the country, currently employing more than 1000 people in R&D function. For over 20 years Alina has been supporting and initiating activities in the area of CSR as well as inclusiveness and diversity , which is her true passion.